Heart drug showdown: which works best when kidneys also fail?

NCT ID NCT07186062

Completed Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at 60 adults with acute decompensated heart failure and kidney impairment. Researchers compared three intravenous heart medications—levosimendan, dobutamine, and milrinone—to see which one improved heart and kidney function best. The goal was to find the most effective option for managing this difficult combination of conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Levosimendan, dobutamine, and milrinone (heart-failure medications given intravenously)
What this could lead to: If one drug proves clearly better, it could guide doctors to choose the most effective treatment for heart failure patients who also have kidney issues.
What could go wrong: This is a small, completed study (60 people) that compares existing drugs, so it won't produce a new treatment. Results may not apply to all patients, and each drug carries risks like low blood pressure or heart rhythm problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE DECOMPENSATED HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardio-renal syndrome congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE DECOMPENSATED HEART FAILURE (ADHF) CARDIORENAL SYNDROME (CRS)

Contacts and locations

Locations

faculty of medicine Ain shams University

Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.